Why Moderna Is Moving Nowhere For Now
At the peak of the hype for COVID-19 vaccine developers, Moderna (MRNA), at a $95.21 high, looked like it would break above $100. Additional government funding announcements, upcoming Phase 3 clinical trial results, and pre-orders should have sent Moderna stock to new highs. Yet the market has a way of reversing a “sure thing” to uncertainty. While BioNTechSE (BNTX) and Novavax (NVAX) get the reward for trading at over $100 (BNTX is now $74 at the time of writing), what should Moderna investors …
